drug

Sulforaphane

sulforaphane
MeSH C016766
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Central South University
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
NCT07652866—Not Yet Recruiting
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
NCT04521868Phase 2Completed
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia
NCT02880462Phase 2Completed

KOLs & investigators

4
Renrong Wu, M.D., Ph.D.KOL score 5
Hua Jin, M.D Ph.D
Jingping Zhao, M.D Ph.D
Jianjun Ou, M.D Ph.D

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Central South University
company
trial
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
NA
trial
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
PHASE2
trial
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Schizophrenia Disorder
indication
KOL
Renrong Wu, M.D., Ph.D.
KOL score 5
person
Hua Jin, M.D Ph.D
KOL score —
person
Jingping Zhao, M.D Ph.D
KOL score —
person
Jianjun Ou, M.D Ph.D
KOL score —
person